

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 18 U.S.C. §208(b)(3)

Stephen George, Ph.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: September 6, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Applications (NDA) 020-287, Fragmin (dalteparin sodium), sponsored by Pfizer, Inc., for the proposed indication of extended treatment of symptomatic venous thromboembolism (VTE), such as proximal deep venous thromboses (DVT) and/or pulmonary embolism (PE), to reduce the recurrence of VTE in patients with cancer, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Consulting	Competitor	Less than \$10,001 per year.
Unrelated Consulting	Competitor	Less than \$10,001 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

/s/
Signature

8/3/06
Date